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Introduction
In Slovenia as well as worldwide, gastric carcinoma is considered as a disease with poor prognosis. Radical surgery which can be performed in only 50-70% of patients 1,2 is a common treatment for localized disease. Long-term outcomes with surgery alone are still relatively poor because disease recurrence was observed in 75% of patients, and in 40-65% of them, the disease recurred locally and/or regionally. [2] [3] [4] A number of studies have been conducted to improve the treatment outcome of these patients and, as a result, postoperative radiochemotherapy was established as a routine treatment in the USA as well as in other countries. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The authors believe that the INT 0116 protocol is safe and acceptable for clinical use. 3, 5, [8] [9] [10] [11] Data on late side effects are scarce. It is suspected that the used radiation fields can cause the damage to the left kidney in some patients, resulting in hypertension and other renal problems. 17 Six months after radiochemotherapy for gastric cancer, Jansen et al. observed a 20% decrease in the function of the left kidney. They believe that the renal impairment may increase over time. 18 In 2001, at the Institute of Oncology Ljubljana, Slovenia, postoperative radiochemotherapy was established as a standard clinical practice in the treatment of patients who had undergone radical resection of non-metastatic gastric adenocarcinoma of stages Ib-IV. The short-term results of this treatment regimen have already been published. 10 The aim of the present report is to present the long-term results of postoperative radiochemotherapy for gastric adenocarcinoma, including late treatment-related toxicity.
Patients and methods
Between 2001 and 2004, 123 patients (79 males, 44 females) with the mean age of 60 years (range: 31-76 years), were treated for gastric adenocarcinoma of TNM stages Ib-IV (nonmetastatic), with postoperative concomitant radiochemotherapy. One hundred and seven (87%) patients had radical resection (R0) of the tumor, and in the remaining 16 (13%) patients, non-radical (R1) resection was made. Distal subtotal, total, During the therapy, the patients were clinically examined and referred for hematological and biochemical blood testing once a week. The therapy-related local and systemic toxicity was assessed according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0. 19 WHO scale was used to determine the performance status of patients and their body weight was measured on weekly basis.
Adjuvant treatment was initiated six weeks after surgery. It consisted of concomitantly applied chemotherapy and radiotherapy. In the chemotherapy part of the protocol, five cycles of 5-FU (425mg/m 2 ) and LV (20 mg/m 2 ) administered as five-day intravenous infusions were planned. The treatment cycle was repeated every 28 days. During radiotherapy, the intensity of chemotherapy was decreased. In the second and third cycle, only 4 and 3 applications of the drugs were administered, respectively. After the completed radiotherapy, the patients received two more five-day chemotherapy cycles.
Irradiation was applied during the second and third cycle of chemotherapy. The patients were irradiated on linear accelerator with 5-15 MV photon beams for 5 days per week, at a daily dose of 1.8 Gy. The irradiation field involved the primary tumor site and regional lymph node areas with a safety margin of 1.5-2 cm. Two opposite (AP-PA) beams were applied. Total irradiation dose was 45 Gy and total irradiation time 5 weeks.
After the completed treatment, followup examinations were performed every three months in the first two years and then at six month intervals to the end of five years. The patients were than referred back to their general practitioner's care and attended follow-up examinations only once per year. The follow-up examination consisted of clinical examination, complete blood count, liver and renal functional tests and measurements of CEA and Ca 19-9. Ultrasound (US) or computed tomography (CT) of the abdomen were performed every six months, chest radiography or CT once a year and endoscopic examination of the upper gastrointestinal tract as clinically indicated. During the follow-up period, any suspected disease relapse or recurrence was confirmed by biopsy.
Statistics
Statistical analysis was performed using personal computer and software statistical package SPSS, version 13 (SPSS Inc., USA).
The main endpoints were as follows: locoregional control (LRC, the event was local and/or regional recurrence); diseasefree survival (DFS, the event was local, regional or systemic recurrence); the disease-specific survival (DSS, the event was death due to gastric adenocarcinoma), and overall survival (OS, the event was death from any cause).
The survival of patients was computed from the date of surgery to the 1 st of May, 2009 (close out date). Survival probability was calculated using Kaplan-Meier estimate 20 , and log rank test 21 was used to evaluate the differences between individual groups of patients. Independent prognostic values of variables that appeared statistically significant on univariate analysis were tested by multivariate Cox regression analysis model. 22 Two-sided tests were used and the differences at p < 0.05 were considered as statistically significant.
Results

Treatment outcome
All 123 patients were evaluable for analysis. Postoperative chemotherapy started 3.6-11.9 weeks after surgery (median 5.9 weeks). Total postoperative treatment time ranged from 4.9-32.6 weeks (median 17.6 weeks), whereas the duration of the radiotherapy part of the protocol ranged from 3.3-18 weeks (median 5.3 weeks). In regard to the intensity of radiotherapy and chemotherapy doses, 82% of patients completed the treatment according to the protocol. There was no treatment-related death. The frequency and severity of early toxic effects of radiochemotherapy are shown in Table 2 . In regard to the late side effects, only renal functional impairment (the rise of creatinine level of grade 1, but without hypertension or other renal impairment) was observed in 5 patients (4.1%). The observed median time interval of creatinine level elevation was 10.5 months (range: 8.9-13.4 months).
On the close-out date, median followup time of all treated patients was 51.8 months (range: 5.3-96.4 months), with the median follow-up time of 64.5 months (range: 51.7-96.4 months) for 56 survivors. In 56 (45.5%) patients, alive at the time of analysis, 53 had no signs of disease. Of 67 (54.5%) dead patients, 60 died of gastric carcinoma, 4 of other causes (stroke, lung cancer, cancer of the caecum, myocardial infarction; 1/4 patients with simultaneous locoregional recurrence), and in 3 patients, the cause of death could not be determined.
After adjuvant radiochemotherapy, disease re-appeared in 62 (50.4%) patients. Local and/or regional recurrence developed in 7 (5.7%) patients in the median time of 18 months (range: 9.7-56.3 months) after surgery. Locoregional failure and systemic dissemination were diagnosed in 11 (8.9%) patients in the median time of 11 months (range: 6.2-25.7 months), and 
Prognostic factors
On univariate analysis of survival, locally advanced disease (pT3-4, pN3, overall TNM stage IV) was predictive for worse LRC and survival compared to early disease stages. In addition, poor outcome of patients was associated also with higher degree of stomach involvement with cancer (whole stomach vs. involvement of individual stomach areas), tumor location in the stomach (cardia vs. other subsites), B orrmann type 4, growth type according to Lauren (diffuse type vs. others), with the presence of vascular and perineurial invasion and intensity of chemotherapy (<5 cycles vs. 5 cycles of chemotherapy) (in all instances p<0.05). T he multivariate analysis showed that the tumor involvement of cardia and low intensity of chemotherapy were independent adverse prognostic factors for DSS and OS. More advanced pT-stage and tumors with diffuse growth type according to Lauren were identified as negative independent prognostic factor for OS. They were also on the threshold of statistical significance for DSS (Table 3) .
Discussion
Short-term results of pooperative treatment with radiochemotherapy for gastric cancer in our population of patients have already been published. 10 As some other authors, we may also conclude that the combined radiotherapy and chemotherapy with 5-FU is feasible, with acceptable toxicity, and seems to have a potential to improve treatment outcome compared to surgery as the sole mode of treatment for this poor prognosis group of patients. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] After a longer follow-up, excellent LRC and acceptable DFS, DSS and OS were confirmed, which concurs with the results from other studies. 5, 6, 8, 9, 11, 13, 23 In the present analysis, the patients with more advanced tumors, cardia involvement, perineurial and vascular invasion had poorer survival. With the prolongation of follow-up time, the diffuse growth type according to Lauren, Borrmann type 4 and low number of chemotherapy cycles, were also recognized as negative prognostic factors for disease outcome. All these factors are considered to be well established negative prognosticators in clinics for patients with gastric cancer or with another malignancies and are also usually mentioned as such in pertinent literature. 4, [24] [25] [26] [27] The subgroup of patients with early, distal tumors in whom distal subtotal resection was performed had no better outcome compared to those who had more advanced disease and, consequently, underwent more extensive surgery. This observation pointed out the potential of adjuvant therapy to neutralize otherwise well established prognostic power of higher tumor stage and tumor's localization. Contrary to our previous analysis 10 , the dose of 5-FU per cycle and pretreatment Hb concentration ≤110 g/l lost their influence on survival. The reason for this finding could be longer follow up and consecutively more adequate statistical analysis.
The results of both multivariate analyses (i.e. the one from the past and the present one) exposed tumors located in the cardia as negative and independent prognosticators, which was pointed out also in other similar studies. 26, 27 In the present analysis, like at the most of analysis of other malignancies 25 , to no surprise, a more advanced pT-stage was established as negative independent prognostic factor for OS, while for DSS it was on the threshold of statistical significance. The patients who received less than five cycles of chemotherapy had worse DSS and OS. It is well known that the intensity of chemotherapy can have an influence on treatment outcome neoplasma. 24, 28 In our series of patients, we didn't notice other serious late toxicities than the rise of creatinine blood level of grade 1. Jansen et al. observed a progressive decrease in the function of the left kidney which was 11% and 52% after 6 and 18 months, respectively. 18 Due to the more accurate conformal radiotherapy planning, we hope there will be less late renal toxicity 29, 30 , however, to approve this, longer follow-up of our patients is needed. Because of high incidence of unresectable disease and distant metastases, this issue is to be addressed in future prospective studies exploring new systemic drugs and regimens. We should pay greater attention to preoperative radiochemotherapy, which could be the best treatment approach also in this type of malignancy, as it is in rectal, esophageal and breast cancer 31 , although more randomized trials are needed to evaluate the survival benefits of this approach.
Conclusions
From the analysis of the treatment results of a group of 123 patients with operable gastric carcinoma and median follow up time of almost 5 years (more than 5 years in survivors), we may conclude that postoperative adjuvant radiochemotherapy with 5-FU and LV can efficiently improve the treatment outcome, particularly in regard to LRC, with acceptable early and late toxicity. Because of high incidence of distant metastases, this issue has to be addressed in well designed future prospective studies exploring new systemic drugs and regimens.
